

Ai-Jun Li, Min-Li Tao, Jing Ma,
Xue-Qin Zhou and Dong-Zhi
Liu*School of Chemical Engineering and
Technology, Tianjin University, Tianjin 300072,
People's Republic of China

Correspondence e-mail: dzliu@tju.edu.cn

Key indicators

Single-crystal X-ray study
 $T = 294$ K
Mean $\sigma(\text{C}-\text{C}) = 0.005$ Å
 R factor = 0.051
 wR factor = 0.117
Data-to-parameter ratio = 16.6For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.1-(2-Methoxyphenyl)-4-[2-(2-methoxyphenyl-
sulfanyl)benzoyl]piperazine

The title compound, $\text{C}_{25}\text{H}_{26}\text{N}_2\text{O}_3\text{S}$, was synthesized from 2-(2-methoxyphenylsulfanyl)benzoic chloride and 1-(2-methoxyphenyl)piperazine. The piperazine ring exhibits a chair conformation.


Received 22 November 2005

Accepted 6 December 2005

Online 10 December 2005

Comment

Substituted diphenyl sulfide derivatives are a class of compounds which display high *in vitro* and *in vivo* affinities for serotonin transporter (SERT), high selectivity for dopamine transporter sites (DAT) and partial selectivity over norepinephrine transporter sites (NET), and have been described as potent and selective SERT ligands.



The title compound, (I), was synthesized from 2-(2-methoxyphenylsulfanyl)benzoic chloride and 1-(2-methoxyphenyl)piperazine. The molecular structure of the title compound is illustrated in Fig. 1. The piperazine ring is in a normal chair conformation.

Experimental

2-(2-Methoxyphenylsulfanyl)benzoic chloride (8 mmol), triethylamine (20 mmol) and 1-(2-methoxyphenyl)piperazine (8 mmol) in




Figure 1
The molecular structure of (I), drawn with 30% probability ellipsoids.

CHCl_3 (60 ml) were stirred at room temperature for 3–4.5 h. After cooling to room temperature, the mixture was washed with 2 M NaOH. The organic layer was evaporated *in vacuo* to dryness to give a sticky yellow oil, which solidified at room temperature (Mehta & Bricaddy, 1997; Wilson & Howie, 1999; Younes *et al.*, 2000). After recrystallization from 60% aqueous ethanol (50–70 ml), the title compound was obtained as a white crystalline solid. Crystals of (I) suitable for X-ray analysis were grown by slow evaporation of an absolute methanol solution at room temperature over 15 d.

Crystal data

$\text{C}_{25}\text{H}_{26}\text{N}_2\text{O}_3\text{S}$	$D_x = 1.260 \text{ Mg m}^{-3}$
$M_r = 434.54$	Mo $K\alpha$ radiation
Monoclinic, $P2_1/c$	Cell parameters from 1945 reflections
$a = 12.483 (3) \text{ \AA}$	$\theta = 2.2\text{--}21.5^\circ$
$b = 16.535 (3) \text{ \AA}$	$\mu = 0.17 \text{ mm}^{-1}$
$c = 12.504 (3) \text{ \AA}$	$T = 294 (2) \text{ K}$
$\beta = 117.451 (3)^\circ$	Block, colourless
$V = 2290.3 (8) \text{ \AA}^3$	$0.40 \times 0.20 \times 0.10 \text{ mm}$
$Z = 4$	

Data collection

Bruker SMART CCD area-detector diffractometer	4695 independent reflections
φ and ω scans	2189 reflections with $I > 2\sigma(I)$
Absorption correction: multi-scan (SADABS; Bruker, 1997)	$R_{\text{int}} = 0.059$
$T_{\text{min}} = 0.935$, $T_{\text{max}} = 0.983$	$\theta_{\text{max}} = 26.4^\circ$
12787 measured reflections	$h = -15 \rightarrow 15$
	$k = -16 \rightarrow 20$
	$l = -13 \rightarrow 15$

Refinement

Refinement on F^2	H-atom parameters constrained
$R[F^2 > 2\sigma(F^2)] = 0.051$	$w = 1/[\sigma^2(F_o^2) + (0.04P)^2]$
$wR(F^2) = 0.117$	where $P = (F_o^2 + 2F_c^2)/3$
$S = 1.03$	$(\Delta/\sigma)_{\text{max}} = 0.001$
4695 reflections	$\Delta\rho_{\text{max}} = 0.22 \text{ e \AA}^{-3}$
282 parameters	$\Delta\rho_{\text{min}} = -0.23 \text{ e \AA}^{-3}$

All H atoms were positioned geometrically and refined as riding, with C–H distances in the range 0.93–0.98 Å and with $U_{\text{iso}}(\text{H}) = 1.2 U_{\text{eq}}(\text{C})$.

Data collection: SMART (Bruker, 1997); cell refinement: SAINT (Bruker, 1997); data reduction: SAINT; program(s) used to solve




Figure 2

The crystal structure of (I), viewed along the a axis

structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Bruker, 1997); software used to prepare material for publication: *SHELXTL*.

References

- Bruker (1997). *SADABS* (Version 2.0), *SMART* (Version 5.1), *SAINT* (Version 5.1) and *SHELXTL* (Version 5.10). Bruker AXS Inc., Madison, Wisconsin, USA.
- Mehta, N. B. & Bricaddy, L. E. (1997). US Patent 4 056 632.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Wilson, A. A. & Houle, S. (1999). *J. Labelled Compd. Radiopharm.* **42**, 1277–1288.
- Younes, S., Labssita, Y., Baziard-Mouysset, G., Payard, M., Rettotri, M. C., Renard, P., Pfeiffer, B. & Caiqnard, D. H. (2000). *Eur. J. Med. Chem.* **35**, 107–121.